Compare · ENOV vs SNN
ENOV vs SNN
Side-by-side comparison of Enovis Corporation (ENOV) and Smith & Nephew SNATS Inc. (SNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENOV and SNN operate in Industrial Specialties (Health Care), so they compete in similar markets.
- SNN is the larger of the two at $13.14B, about 9.8x ENOV ($1.34B).
- SNN has been more active in the news (7 items in the past 4 weeks vs 6 for ENOV).
- SNN has more recent analyst coverage (22 ratings vs 19 for ENOV).
- Company
- Enovis Corporation
- Smith & Nephew SNATS Inc.
- Price
- $23.43+4.25%
- $30.94+1.88%
- Market cap
- $1.34B
- $13.14B
- 1M return
- +3.01%
- -
- 1Y return
- -32.27%
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 6
- 7
- Recent ratings
- 19
- 22
Enovis Corporation
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Latest ENOV
- SEC Form SCHEDULE 13G filed by Enovis Corporation
- William Blair resumed coverage on Enovis Corporation
- SEC Form 3 filed by new insider Singleton Laura Lee
- Enovis to Host First Quarter 2026 Results Conference Call on May 7th
- SEC Form DEFA14A filed by Enovis Corporation
- SEC Form DEF 14A filed by Enovis Corporation
- SEC Form 4 filed by Ortiz Christine
- Amendment: SEC Form SCHEDULE 13G/A filed by Enovis Corporation
- Chief Administrative Officer Engert Oliver bought $23,740 worth of shares (1,000 units at $23.74), increasing direct ownership by 2% to 48,640 units (SEC Form 4)
- Chief Administrative Officer Engert Oliver bought $23,930 worth of shares (1,000 units at $23.93), increasing direct ownership by 2% to 47,640 units (SEC Form 4)
Latest SNN
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- New data for Smith+Nephew's CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant demonstrates superior pain relief and functional gains at 5-years
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Amendment: SEC Form 6-K/A filed by Smith & Nephew SNATS Inc.
- Smith+Nephew's REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.